PD-L1 (CPS) >= 10
About
Biomarker Type: Protein expression
Present: True
Marker: PD-L1
Unit: Combined Positive Score (CPS)
Equality: >=
Value: 10
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 (CPS) >= 10 | Adenocarcinoma of the Gastroesophageal Junction | Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 10 | Esophageal Adenocarcinoma | Pembrolizumab | |
| Sensitivity (+) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Paclitaxel, Pembrolizumab | |
| Sensitivity (+) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine, Pembrolizumab | |
| Sensitivity (+) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Paclitaxel, Pembrolizumab |